A general model for genetic regulation of turnover of glycosaminoglycans suggests a possible procedure for prediction of severity and clinical progress of mucopolysaccharidoses

Medical Hypotheses

Volumn 62, Issue 6, 2004, Pages 986-992

  Wegrzyn G ^a   Wegrzyn A ^b   Tylki Szymanska A ^c  

^a UNIVERSITY OF GDA SK   (Poland)

^b INSTITUTE OF BIOCHEMISTRY AND BIOPHYSICS   (Poland)

^c CHILDREN'S MEMORIAL HEALTH INSTITUTE   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME; GLYCOSAMINOGLYCAN; HYDROLASE; LEVO IDURONIDASE; LYSOSOME ENZYME;

ACCURACY; BIOACCUMULATION; BIOCHEMISTRY; BIODEGRADATION; CARBOHYDRATE METABOLISM; CLINICAL FEATURE; CORRELATION ANALYSIS; DISEASE COURSE; DISEASE SEVERITY; ENZYME ACTIVITY; ENZYME DEFICIENCY; ENZYME REGULATION; ENZYME SUBSTRATE; GENE EXPRESSION; GENE MUTATION; GENETIC CODE; GENETIC DISORDER; GENETIC REGULATION; GLYCOSAMINOGLYCAN METABOLISM; HUMAN; HURLER SYNDROME; HYPOTHESIS; LYSOSOME; LYSOSOME STORAGE DISEASE; MODEL; MUCOPOLYSACCHARIDOSIS; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REGULATORY MECHANISM; REVIEW; SCHEIE SYNDROME;

EID: 2542505572     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2003.12.027     Document Type: Article

References (54)

1. Neufeld EF, Muenzer J. The mucopolysaccharidoses. In: Scriver CR, Beaudet EL, Sly WS, Valle D, editors. The metabolic and molecular bases of inherited disease. New York: McGraw-Hill; 1995. p. 2465-94.
2. Park PW, Reizes O, Bernfield M. Cell surface heparan sulfate proteoglycans: selective regulators of ligand-receptor encounters. J Biol Chem 2000;275:29923-6.
3. Gallagher JT. Heparan sulfate: growth control with a restricted sequence menu. J Clin Invest 2001;108:357-61.
4. Grobe K, Ledin J, Ringvall M, Holmborn K, Forsberg E, Esko JD, et al. Heparan sulfate and development: differential roles of the N-acetylglucosamine N-deacetylase/N-sulfotransferase isozymes. Biochim Biophys Acta 2002;1573:209-15.
5. Honke K, Taniguchi N. Sulfotransferases and sulfated oligosaccharides. Med Res Rev 2002;22:637-754.
6. Iivanainen E, Kahari VM, Heino J, Elenius K. Endothelial cell-matrix interactions. Microsc Res Tech 2003;60:13-22.
7. Cavalcante LA, Garcia-Abreu J, Moura-Neto V, Silva LC, Weissmuller G. Modulators of axonal growth and guidance at the brain midline with special reference to glial heparan sulfate proteoglycans. Ann Acad Bras Cienc 2002;74:691-716.
8. Lander AD, Selleck SB. The elusive functions of proteoglycans. In vivo veritas. J Cell Biol 2000;148:227-32.
9. Perrimon N, Bernfield M. Specificities of heparan sulfate proteoglycans in developmental processes. Nature 2000;404:725-58.
10. Forsberg E, Kjellen L. Heparan sulfate: lessons from knockout mice. J Clin Invest 2001; 108:175-80.
11. Lin X, Wei G, Shi ZZ, Dryer L, Esko JD, Wells DE, et al. Disruption of gastrulation and heparan sulfate biosynthesis in EXT1-deficient mice. Dev Biol 2000;224:299-311.
12. Humphries DE, Wong GW, Friend DS, Gurish MF, Qiu WT, Huang CF, et al. Heparin is essential for the storage of specific granule proteases in mast cells. Nature 1999;400:769-72.
13. Forsberg E, Pejler G, Ringvall M, Lunderius C, Tomasini-Johansson B, Kusche-Gullberg M, et al. Abnormal mast cells in mice deficient in a heparin-synthesizing enzyme. Nature 1999;400:773-6.
14. Merry CLR, Wilson VA. Role of heparan sulfate-2-O-sulfotransferase in the mouse. Biochim Biophys Acta 2002;1573:319-27.
15. Hinek A, Wilson SE. Impaired elastogenesis in Hurler disease: dermatan sulfate accumulation linked to deficiency in elastin-binding protein and elastic fiber assembly. Am J Pathol 2000;156:925-38.
16. Hopwood JJ, Morris CP. The mucopolysaccharidoses: diagnosis, molecular genetics and treatment. Mol Biol Med 1990;7:381-404.
17. Tylki-Szymańska A, Czartoryska B, Bunge S, van Diggelen OP, Kleijer WJ, Poorthuis BJ, et al. Clinical, biochemical and molecular findings in a two-generation Morquio A family. Clin Genet 1998;53:369-74.
18. Roubicek M, Gehler J, Spranger J. The clinical spectrum of α-L-iduronidase deficiency. Am J Med Genet 1985;20:471-81.
19. Scott HS, Bunge S, Gal A, Clarke LA, Morris CP, Hopwood JJ. Molecular genetics of mucopolysaccharidosis type I: diagnostic, clinical and biological implications. Hum Mutat 1995;6:203-88.
20. Bunge S, Kleijer WJ, Steglich C, Beck M, Zuther C, Morris CP, et al. Mucopolysaccharidosis type I: identification of 8 novel mutations and determination of the frequency of the two common α-L-iduronidase mutations (W402X and Q70X) among European patients. Hum Mol Genet 1994;3:861-6.
21. Bunge S, Clements PR, Byers S, Kleijer WJ, Brooks DA, Hopwood JJ. Genotype-phenotype correlations in mucopolysaccharidosis type I using enzyme kinetics, immunoquantification and in vitro turnover studies. Biochim Biophys Acta 1998;1407:249-56.
22. Beesley CE, Meaney CA, Greenland G, Adams V, Vellodi A, Young EP, et al. Mutation analysis of 85 mucopolysaccharidosis type I families: frequency of known mutations, identification of 17 novel mutations and in vitro expression of missense mutations. Hum Genet 2001;109:503-11.
23. Taylor HA, Thomas GH. Pseudodeficiency of α-L-iduronidase. J Inherit Metab Dis 1994;16:1058-9.
24. Gatti R, Borrone C, Filocamo M, Pannone N, DiNatale P. Prenatal diagnosis of mucopolysaccharidosis I: a special difficulty arising from an unusually low enzyme activity in mother's cells. Prenatal Diag 1985;5:149-54.
25. Whitley CB, Gorlin RJ, Krivit W. A nonpathogenic allele (I-W) for low α-L-iduronidase enzyme activity via-a-vis prenatal diagnosis of Hurler syndrome. Am J Med Genet 1987;28:233-43.
26. Aronovitch EL, Pan D, Whitley CB. Molecular genetic defect underlying α-L-iduronidase pseudodeficiency. Am J Hum Genet 1996;58:75-85.
27. McDowell GA, Cowan TM, Blitzer MG, Greene CL. Intrafamiliar variability in Hurler syndrome and Sanfilippo syndrome type A: implications for evolution of new therapies. Am J Med Genet 1993;47:1092-5.
28. Wanger DA, Willimas C. Screening for lysosomal disorders. In: Hommes FA, editor. Techniques in diagnostic human biochemical genetics, a laboratory manual. New York: Willey-Liss; 1993. p. 587-617.
29. Neidhardt FC, Curtiss III R, Ingraham JL, Lin ECC, Low KB, Magasanik B, et al., editors. Escherichia coli and Salmonella: cellular and molecular biology. Washington, DC: American Society for Microbiology; 1996.
30. Taylor K, Wȩgrzyn G. Replication of coliphage lambda DNA. FEMS Microbiol Rev 1995;17:109-19.
31. Taylor K, Wȩgrzyn G. Regulation of bacteriophage λ replication. In: Busby SJW, Thomas CM, Brown NL, editors. Molecular microbiology, Berlin; 1998. p. 81-97.
32. Wȩgrzyn G, Wȩgrzyn A, Barańska S, Czyż A. Regulation of bacteriophage lambda development. Recent Res Dev Virol 2001;3:375-86.
33. Chamoles NA, Blanco M, Gaggioli D. Diagnosis of α-L-iduronidase deficiency in dried blood spots on filter paper: the possibility of newborn diagnosis. Clin Chem 2001;47:780-1.
34. Chamoles NA, Blanco MB, Gaggioli D, Casentini C. Hurler-like phenotype: enzymatic diagnosis in dried blood spots on filter paper. Clin Chem 2001;47:2012-98.
35. Volpi N. Purification of heparin, dermatan sulfate and chondroitin sulfate from mixtures by sequential precipitation with various organic solvents. J Chromatogr B 1996;685:27-34.
36. Fischer J. Drug-induced glycosaminolycan storage: dose-dependent changes in the pattern of accumulated glycosaminoglycans in cultured bovine and human fibroblasts. Biochem Pharmacol 1996;52:1331-7.
37. Shinjo SK, Prates NEVB, Oba SM, Sampaio LO, Nader HB. Distribution and composition of glycosaminoglycans in the left human coronary arterial branches under myocardial bridge. Atherosclerosis 1999;143:363-8.
38. Goulas A, Papakonstantinou E, Karakiulakis G, Mirtsou-Fidani V, Kalinderis A, Hatzichristou DG. Tissue structure-specific distribution of glycosaminoglycans in the human penis. Int J Biochem Cell Biol 2000;32:975-82.
39. Barbosa I, Garcia S, Barbier-Chassefiere V, Carulle J-P, Martelly I, Papy-Garcia D. Improved and simple mico assay for sulfated glycosaminoglycans quantification in biological extracts and its use in skin and muscle tissue studeis. Glycobiology 2003;13:647-53.
40. Kakkis ED, Muenzer J, Tiller GE, Waber L, Belmont J, Passage M, et al. Enzyme-replacement therapy in mucopolysaccharidosis I. New Eng J Med 2001;344:182-8.
41. Kakkis ED. Enzyme replacement therapy for mucopolysaccharide storage disorders. Expert Opin Investig Drugs 2002;11:657-85.
42. Schiffmann R, Brady RO. New prospects for the treatment of lysosomal storage disorders. Drugs 2002;62:733-42.
43. Wraith JE. Enzyme replacement therapy in mucopolysaccharidosis typr I: progress and emerging difficulties. J Inherit Metab Dis 2001;24:245-50.
44. Sly WS, Vogler C. Brain-directed gene therapy for lysosomal storage disease: going well beyond the blood-brain barrier. Proc Natl Acad Sci USA 2002;99:5760-2.
45. Leinekugel P, Michel S, Conzelmann E, Sandhoff K. Quantitative correlation between the residual activity of β-hexosaminidase A and arylsulfatase A and the severity of the resulting lysosomal storage disease. Hum Genet 1992;88:513-23.
46. Barranger JA, O'Rourke E. Lessons learned from the development of enzyme therapy for Gaucher disease. J Inherit Metab Dis 2001;24(Suppl. 2):89-96.
47. Grobe K, Esko JD. Regulated translation of heparan sulfate N-acetylglucosamine deacetylase/N-sulfotranferase isozymes by structured 5′-untranslated regions and internal ribosome entry sites. J Biol Chem 2002;277:30699-706.
48. Borjigin J, Deng J, Sun X, De Jesus M, Liu T, Wand MM. Diurnal pinal 3-0-sulphotransferase 2 expression controlled by beta-andrenergic repression. J Biol Chem 2003;278:16315-61319.
49. Inatani M, Yamaguchi Y. Gene expression of EXT1 and EXT2 during mouse brain development. Brain Res Dev Brain Res 2003;141:129-36.
50. Moreira CR, Porcionatto MA, Dietrich CP, Nader HB. Effect of bradykinin and PMA on the synthesis of proteoglycan during the cell cycle of endothelial cell in culture. Int Immunopharmacol 3: 293-98.
51. Murata M, Bonassar LJ, Wright M, Mankin HJ, Towle CA. A role for the interleukin-1 receptor in the pathway linking static mechanical compression to decreased proteoglycan synthesis in surface articular cartilage. Arch Biochem Biophys 2003;413:229-35.
52. Nandini CD, Sambaiah K, Salimath PV. Dietary fibers ameliorate decreased synthesis of heparan sulphate in streptozotocin induced diabetic rats. J Nutr Biochem 2003;14:203-10.
53. Sauerland K, Raiss RX, Steinmeyer J. Proteoglycan metabolism and viability of articular cartilage explants as modulated by the frequency of intermittent loading. Osteoarthritis Cartilage 2003;11:343-50.
54. Turnbull J, Drummond K, Huang Z, Kinnunen T, Ford-Perriss M, Murphy M, et al. Heparan sulphate sulphotransferase expression in mice and Caenorhabditis elegans. Biochem Soc Trans 2003;31:343-8.